IR@PKUHSC  > 北京大学药学院
学科主题药学
N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer
Wang, Yue-Ming1,2; Hu, Lai-Xing1,2,4; Liu, Zhen-Ming3; You, Xue-Fu1,2; Zhang, Sheng-Hua1,2; Qu, Jing-Rong5; Li, Zhuo-Rong1,2; Li, Yan5; Kong, Wei-Jia1,2; He, Hong-Wei1,2; Shao, Rong-Guang1,2; Zhang, Liang-Ren5; Peng, Zong-Gen1,2; Boykin, David W.4; Jiang, Jian-Dong1,2
刊名CLINICAL CANCER RESEARCH
2008-10-01
DOI10.1158/1078-0432.CCR-08-0550
14期:19页:6218-6227
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]SPINDLE ASSEMBLY CHECKPOINT ; TUMOR-CELL LINES ; MICROTUBULE DYNAMICS ; POLYMERIZATION DYNAMICS ; MITOTIC CHECKPOINT ; INDUCED APOPTOSIS ; ANTICANCER DRUGS ; M-PHASE ; DEATH ; AGENTS
英文摘要

Purpose: We have synthesized a new tubulin ligand N-(2,6-dimethoxypyridine-3-yl) -9-methylcarbazole-3-sulfonamide (IG-105). This work investigates its anticancer effect and mechanism.

Experimental Design: Anticancer efficacy was evaluated at the molecular target, cancer cells and nude mice. The mechanism was explored at submolecular, molecular, and cellular levels.

Results: IG-105 showed a potent activity against human leukemia and solid tumors in breast, liver, prostate, lung, skin, colon, and pancreas with IC(50) values between 0.012 and 0.298 mu mol/L. It was also active in drug-resistant tumor cells and not a P-glycoprotein substrate. It inhibited microtubule assembly followed by M-phase arrest, Bcl-2 inactivation, and then apoptosis through caspase pathways. The colchicine pocket on tubulin is the binding site of IG-105. Nude mice experiments showed that IG-105 monotherapy at 100 mg/kg i.p. (q2d) yielded 81% inhibition of Bel-7402 hepatoma growth and at 275 mg/kg i.p. (q2d) completely inhibited the tumor growth. MCF-7 breast cancer in nude mice showed a similar therapeutic response to IG-105. Acute toxicity of IG-105 was not found even at 1,000 mg/kg i.p. In combination with oxaliplatin or doxorubicin, IG-105 converted each of these subcurative compounds into a curative treatment with complete inhibition for tumor growth in the hepatoma-bearing nude mice. The combination was more active than either drug. In no experiment was toxicity increased by combination chemotherapy.

Conclusions: IG-105 inhibits microtubule assembly by binding at colchicine pocket. It shows a potent anticancer activity in vitro and in vivo and has good safety in mice. We consider IG-105 merits further investigation.

语种英语
WOS记录号WOS:000260142500035
项目编号30371673
资助机构National Natural Science Foundation of China ; Ministry of Science and Technology
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/68251
专题北京大学药学院
北京大学药学院_药物化学系
作者单位1.Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China
2.Peking Union Med Coll, Beijing 100021, Peoples R China
3.Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100871, Peoples R China
4.Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA
5.Mt Sinai Sch Med, Dept Med, New York, NY USA
推荐引用方式
GB/T 7714
Wang, Yue-Ming,Hu, Lai-Xing,Liu, Zhen-Ming,et al. N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer[J]. CLINICAL CANCER RESEARCH,2008,14(19):6218-6227.
APA Wang, Yue-Ming.,Hu, Lai-Xing.,Liu, Zhen-Ming.,You, Xue-Fu.,Zhang, Sheng-Hua.,...&Jiang, Jian-Dong.(2008).N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer.CLINICAL CANCER RESEARCH,14(19),6218-6227.
MLA Wang, Yue-Ming,et al."N-(2,6-Dimethoxypyridine-3-yl)-9-Methylcarbazole-3-Sulfonamide as a Novel Tubulin Ligand against Human Cancer".CLINICAL CANCER RESEARCH 14.19(2008):6218-6227.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Yue-Ming]的文章
[Hu, Lai-Xing]的文章
[Liu, Zhen-Ming]的文章
百度学术
百度学术中相似的文章
[Wang, Yue-Ming]的文章
[Hu, Lai-Xing]的文章
[Liu, Zhen-Ming]的文章
必应学术
必应学术中相似的文章
[Wang, Yue-Ming]的文章
[Hu, Lai-Xing]的文章
[Liu, Zhen-Ming]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。